




# CONTRIBUTING TO THE FIGHT AGAINST DENGUE



Takeda believes that mosquito-borne infectious diseases, including dengue, are critical threats to public health and is working on a vaccine candidate to help reduce disease burden.

Takeda's dengue vaccine candidate (TAK-003) is based on a modified strain of dengue virus, which provides the genetic 'backbone' for all four vaccine viruses and exposes the individual to a number of components of the virus that could be important in protection against future infection with dengue virus.



## Phase 3

Tetravalent Immunization against Dengue Efficacy Study (TIDES)

TAK-003 is currently in the pivotal **Phase 3 TIDES** trial in dengue-endemic Latin American and Asian Countries.<sup>1</sup>

**TIDES is Takeda's largest interventional clinical trial to date.**

Over 20,000 healthy children and adolescents were enrolled in the trial from **eight dengue-endemic countries** in Latin America (Brazil, Colombia, Panama, Dominican Republic, Nicaragua) and Asia Pacific (Philippines, Thailand, Sri Lanka). These are areas where there are unmet needs in dengue prevention and where severe dengue is the leading cause of serious illness and death among children.



The double-blind, randomized and placebo-controlled Phase 3 trial is investigating the **safety and efficacy** of a two dose regimen of TAK-003, administered three months apart, to protect children and adolescents against all four strains of dengue virus, regardless of previous dengue exposure.<sup>1</sup>



Takeda is working to secure the necessary evidence from clinical trials to support the use of its dengue vaccine candidate in people who need it, including healthy children and adults in dengue endemic and non-endemic countries.

### Reference

<sup>1</sup> ClinicalTrials.gov. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). 2017. Retrieved March 2019. <https://clinicaltrials.gov/ct2/show/NCT02747927?term=den-301&rank=1>